Terminal2 — Card #36: Prion Disease (CJD / Fatal Insomnia)

S01 Everyone

What Is It

Definition, mechanism, and the clinical reality of prion disease at end of life. What the hospice team needs to understand on day one — because the disease may be weeks ahead of the team.

US Incidence

~350–400

Cases annually — sporadic CJD accounts for ~85%; total prion disease incidence ~1–2 per million population per year.^[1]

Speed of Decline

4–6 mo

Median survival from symptom onset in sCJD — among the fastest fatal dementias in medicine. 90% dead within 1 year.^[2]

Diagnostic Delay

3–5 mo

Average from first symptoms to diagnosis. Patients are seen by multiple specialists before prion disease is considered.^[3]

Uniformly Fatal

100%

Case fatality rate — there is no treatment that alters the course of any prion disease. Every clinical decision is a comfort decision from the moment of diagnosis.^[4]

🧬 The Biology of Prion Disease

Prion diseases are caused by the misfolding of a normal cellular protein — the prion protein (PrP^C) — into a pathological conformer (PrP^Sc) that is resistant to normal cellular degradation and propagates by inducing further misfolding of native protein. The accumulating abnormal protein destroys neurons, creating the characteristic spongiform vacuolation of the brain that gives the disease its histological signature. The clinical consequence is a neurological catastrophe that proceeds at a speed unmatched by any other neurodegenerative disease: dementia, ataxia, myoclonus, visual disturbance, and behavioral change arriving within weeks of each other and progressing to akinetic mutism and death within months.^[5]

Prion disease is not a disease that arrives slowly. Sporadic CJD (sCJD) — accounting for 85% of cases — arrives without warning, without hereditary predisposition in most cases, and without any known exposure. A person who was working, driving, and attending family events in January may be in a hospice bed in March and dead before summer. The family of an sCJD patient is not managing a chronic illness. They are managing an ambush. The hospice clinician who walks through the door for the first time is not entering a home that has adjusted to illness — they are entering a home in acute crisis, often still in disbelief, with safety questions they are afraid to ask, and grief that has had no time to form into anything coherent.^[2]

What makes prion disease unique in hospice is threefold: the speed that compresses years of grief into weeks; the safety questions that arrive with the diagnosis and require clear clinical answers; and the complete absence of disease-modifying treatment, which means every clinical decision at every visit is a comfort decision and nothing else. The hospice team does not have to explain why treatment is no longer being offered — there was never a treatment to offer. What the team can give is what no other provider has had time or training to give: comfort, safety clarity, and the preparation for what is coming, which is coming fast.^[6]

The subtypes differ in their speed and trigger: sporadic CJD (sCJD, 85%) — median survival 4–6 months; familial CJD and related genetic prion diseases (15%) — caused by autosomal dominant PRNP mutations, more variable trajectory; variant CJD (vCJD) — linked to BSE exposure, younger patients, 13–14 month median survival; Fatal Familial Insomnia (FFI) — dominated by progressive insomnia and autonomic failure, 7–36 month median; Gerstmann-Sträussler-Scheinker syndrome (GSS) — predominantly cerebellar, 2–10 year trajectory. In hospice practice, the majority of patients will have sporadic CJD, and the clinical framing must reflect that speed.^[7]

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"The first thing I say when I walk into a CJD home is: 'You cannot catch this by living here and taking care of your person.' I say it before they ask, because if I wait for them to ask, they may never work up the courage — and in the meantime they're sleeping in a different room from someone who is dying and needs them beside them."

— Waldo, NP · Terminal2

S02Clinician

How It's Diagnosed

Diagnostic workup, key tests, and what to look for in hospice records. Most patients arrive with an established or probable diagnosis — this section helps you read it and understand the diagnostic journey the family has been through.

Diagnostic Workup

MRI brain with DWI: The most important diagnostic imaging — cortical ribboning (restricted diffusion in the cortex, basal ganglia, and thalamus in characteristic patterns); pulvinar sign in variant CJD (bilateral high signal in the posterior thalamus). MRI DWI is the most sensitive imaging marker, abnormal in ~90% of sCJD. An experienced neuroradiologist should review the MRI — the DWI pattern of CJD is characteristic and should prompt immediate specialist consultation.^[8]
CSF RT-QuIC (Real-Time Quaking-Induced Conversion): Current gold standard CSF test for prion disease. Sensitivity ~95% when combined with the clinical picture. This has largely replaced 14-3-3 protein as the primary CSF diagnostic test.^[9]
CSF 14-3-3 protein: Older marker; less specific than RT-QuIC but still used. Total tau markedly elevated in CJD. CSF protein may be mildly elevated. Normal cell count — CJD does not cause pleocytosis, which helps distinguish it from encephalitis.
EEG: Periodic sharp wave complexes, typically 1–2 Hz, often triphasic; present in ~60–70% of sCJD. Characteristic but not pathognomonic. May be absent in early or variant CJD. The periodic sharp wave complexes correlate with myoclonic jerks clinically.^[10]
PRNP gene sequencing: Recommended in all prion disease cases regardless of family history. Identifies codon 129 polymorphism (MM, MV, VV — homozygosity increases susceptibility to sCJD and vCJD) and pathogenic mutations: E200K (most common familial CJD), D178N (familial CJD vs. FFI determined by codon 129 haplotype), V210I, P102L (GSS), octapeptide repeat insertions. Approximately 15% of apparently sporadic cases have a pathogenic PRNP mutation.^[11]
CSF biomarkers: Phosphorylated tau and neurofilament light chain — highly elevated in CJD, reflecting rapid neuronal destruction. Supportive but not diagnostic alone.
Neuropathological confirmation: Brain biopsy or post-mortem autopsy — definitive diagnosis by immunohistochemistry for PrP^Sc deposition, spongiform vacuolation, neuronal loss, and gliosis. Brain biopsy is rarely appropriate in the hospice context. Post-mortem brain donation for surveillance and research should be offered to all families.

What to Look for in Hospice Records

PRNP genetic status: Has the patient had PRNP sequencing? Is there a documented pathogenic mutation? If yes, the adult children require urgent genetic counseling referral — this is a first-visit obligation.^[12]
RT-QuIC result: Was it positive, negative, or not performed? A positive RT-QuIC with compatible MRI DWI findings provides a probable diagnosis with high confidence. A negative RT-QuIC does not exclude prion disease in the right clinical context.
MRI DWI findings documented: Look for specific mention of cortical ribboning, basal ganglia signal change, or pulvinar sign. If only a general radiologist report is present, the DWI interpretation may have been missed — the pattern is specific and requires prion disease awareness.
Codon 129 polymorphism: MM homozygosity is overrepresented in sCJD and vCJD. MV and VV patients may have atypical presentations. Relevant to prognosis and family genetic risk assessment.
Neurology consultation documented: Prion disease should have been reviewed by a neurologist with experience in rapidly progressive dementias. If not, the diagnosis may still be evolving — contact the referring neurologist.
National Prion Disease Pathology Surveillance Center (NPDPSC) contact: Has the case been reported? The NPDPSC at Case Western Reserve University provides diagnostic support, surveillance, and referral resources. All confirmed or suspected cases should be reported.
Prior corticosteroid or immunosuppressant trial: Many CJD patients receive empirical corticosteroids during the diagnostic odyssey when autoimmune encephalitis is on the differential. Document this — it should be reassessed and typically discontinued at enrollment once the diagnosis is confirmed.

💡 For families: Understanding the diagnostic journey

💡 Para las familias

Most CJD patients have seen multiple specialists — neurologists, psychiatrists, infectious disease physicians — before the diagnosis was made. This diagnostic odyssey of 3–5 months, during which treatable conditions were considered and eliminated, is a source of profound grief and sometimes anger. The family who arrives at hospice enrollment has already lived through months of hope-and-disappointment cycles. Acknowledging this explicitly — "I understand you've been through a very long road to get to this diagnosis, and that road was painful" — is one of the most important things a clinician can say in the first visit. The diagnostic workup is now essentially complete. The focus of every visit from this point forward is entirely on comfort, safety, and preparation for what comes next.

La mayoría de los pacientes con ECJ han visto a múltiples especialistas antes de que se hiciera el diagnóstico. Próximamente en español.

S03Everyone

Causes & Risk Factors

Disease mechanisms, subtypes, hereditary risk factors, and the clinical implications of each. Relevant for family conversations, genetic counseling referrals, and answering the question every family asks: "Why did this happen?"

Disease Mechanisms & Subtypes

Sporadic CJD (sCJD) — 85% of cases: No identified exogenous source or genetic mutation in most cases. The current hypothesis is spontaneous misfolding of native PrP^C occurring stochastically — the annual incidence of ~1–2 per million is consistent with a rare spontaneous event. Codon 129 MM homozygosity is a susceptibility factor. No behavioral, dietary, occupational, or environmental factor has been identified as a reliable risk factor for sCJD.^[1]
Genetic prion disease (fCJD, GSS, FFI) — 15%: Autosomal dominant inheritance of pathogenic PRNP mutations. Penetrance approaching 100% for most mutations. Includes familial CJD (E200K most common globally), Gerstmann-Sträussler-Scheinker syndrome (P102L), and Fatal Familial Insomnia (D178N with Met at codon 129 on the mutant allele).^[13]
Variant CJD (vCJD): Dietary exposure to BSE-contaminated beef products — UK epidemic 1980s–1990s. Blood transfusion transmission from vCJD-infected donors documented in UK. Extremely rare in the US. Younger patients (median age ~28 years at onset); pulvinar sign on MRI; longer survival (13–14 months).^[14]
Iatrogenic CJD (iCJD): Transmission via cadaveric dura mater grafts, corneal grafts, cadaveric pituitary hormone preparations (pre-recombinant era), and inadequately sterilized neurosurgical instruments. Now rare due to sterilization protocols. Prions are not inactivated by standard autoclave sterilization — dedicated instrument protocols required.^[15]

Hereditary & Genetic Risk Factors

PRNP mutations — the definitive hereditary risk: Autosomal dominant; lifetime penetrance approaching 100% for most pathogenic variants. The adult children of a patient with a confirmed pathogenic PRNP mutation have a 50% probability of having inherited it. This is the highest-stakes genetic counseling situation in prion disease — and it arrives in the middle of an acute family crisis.^[11]
E200K mutation: Most common pathogenic variant globally. Geographic clusters in people of Libyan Jewish, Chilean, Slovak, and other specific ancestries. Clinical presentation similar to sCJD. Median survival 5–6 months from onset.
D178N mutation: The same mutation causes either familial CJD or Fatal Familial Insomnia depending on the codon 129 genotype on the mutant allele: Met129 → FFI; Val129 → familial CJD. FFI presents with progressive insomnia, autonomic dysregulation, and eventually dementia.
P102L mutation (GSS): Predominantly cerebellar syndrome with slower progression (2–10 years). Dementia is a later feature. Younger onset than sCJD.
Codon 129 polymorphism: MM homozygosity predisposes to sCJD and vCJD. MV heterozygosity appears protective. VV homozygosity associated with specific sCJD subtypes with atypical features. Important for risk assessment in asymptomatic relatives.^[16]
No modifiable risk factors: There is no diet, behavior, occupation, or environmental exposure that has been established as a risk factor for sporadic CJD. Patients and families who ask "what caused this?" deserve the direct answer: we do not know, and there is nothing they did or did not do that caused this.

❤️ For families: "Why did this happen?"

Sporadic CJD arrives without warning and without cause. There is no food, exposure, or decision that caused this. The spontaneous misfolding of a single protein, happening once in a million people per year at random, is not caused by anything anyone did. The family who is quietly asking whether they caused this — by the food they served, the places they traveled, the decisions they made — needs to hear this directly: "Nothing you did caused this. Nothing could have prevented it. This is not your fault in any way." Say it plainly and say it early. The guilt is there even when it is never spoken.

⚕ Clinician note: Genetic counseling is a first-visit obligation in familial prion disease

If the patient has a confirmed or suspected pathogenic PRNP mutation — E200K, D178N, P102L, or any other documented variant — the hospice clinician must facilitate genetic counseling referral at the first visit without exception. Adult children who are asymptomatic have a 50% chance of having inherited a mutation with near-100% penetrance and no treatment. The National Prion Disease Pathology Surveillance Center (NPDPSC) at Case Western Reserve University (1-800-NPDPSC1) provides referral resources and support. A genetic counselor with prion disease experience is available through major academic medical centers. This referral can save lives.^[12]

S04ClinicianEveryone

Treatments & Procedures

There is no disease-modifying therapy for prion disease. Every clinical decision at every visit is a comfort decision. This section covers what has been tried, why it failed, and what the entire clinical focus must be.

There is no disease-modifying treatment for any human prion disease. This is the defining clinical reality of prion disease and must be communicated clearly, compassionately, and completely at the first visit. Extensive preclinical research has identified multiple potential therapeutic targets — prion protein expression suppression, anti-prion antibodies, compounds that prevent PrP^C-to-PrP^Sc conversion — and clinical trials of quinacrine, pentosan polysulfate, flupirtine, and doxycycline have been conducted and uniformly failed to demonstrate clinical benefit.^[17] Gene silencing approaches using antisense oligonucleotides targeting PRNP are in early clinical trial for genetic prion disease and represent the most promising current research direction — but they are not available outside of trials, and they do not apply to the patient already in hospice.^[18]

The hospice clinician must be prepared to say clearly: "There is no treatment that changes the course of prion disease. Everything we can do is focused on keeping your person comfortable." This statement must be delivered with complete honesty and without false hope, and must be followed immediately by what can be done — not left in the clinical vacuum of what cannot. The comfort management of prion disease is specific, evidence-guided, and genuinely effective at reducing suffering. The absence of disease modification does not mean the absence of meaningful clinical intervention.

Disease-Modifying Research — All Negative

Quinacrine: An antimalarial studied on the basis of in vitro prion-clearing properties. Two randomized trials (PRION-1 in UK, UCSF trial in US) showed no survival benefit. Not recommended.^[17]
Pentosan polysulfate: Studied via intraventricular infusion in compassionate use cases. No controlled trial evidence of benefit. No longer used.
Doxycycline: The DOXYCJD trial (Italy, double-blind RCT) showed no survival benefit in symptomatic patients. A prevention trial in asymptomatic E200K carriers is ongoing but not applicable to hospice patients.
Flupirtine: Neuroprotective in vitro; no benefit in CJD in clinical trial (German study). Withdrawn from market in Europe for hepatotoxicity.
Antisense oligonucleotides (ASOs) targeting PRNP: Currently in early Phase I/II trial for genetic prion disease (Ionis Pharmaceuticals / Broad Institute). Mechanism of action — reduce PrP^C expression to reduce substrate for misfolding. Not available outside of trials. The most promising active research direction.^[18]

Symptomatic Management — The Entire Clinical Focus

Myoclonus management (first priority): Clonazepam 0.5–2 mg TID — the most effective antimyoclonic agent and the first-line treatment for prion disease myoclonus; also addresses anxiety and agitation; available in liquid for PEG. Valproate 500–1000 mg BID — additional antiepileptic benefit. Levetiracetam 500–1000 mg BID — adjunct for both myoclonus and seizure; available in liquid and IV formulation.^[19]
Seizure management: Levetiracetam first-line; clonazepam adjunct; acute rescue with buccal or intranasal midazolam (5–10 mg). Family training on rescue medication administration is essential — seizure can occur at any time and the family must be prepared before it happens, not during it.
Anxiety and agitation management: Early CJD behavioral symptoms (anxiety, agitation, paranoia, behavioral disinhibition) are among the most distressing for families. Treat aggressively. Quetiapine 12.5–50 mg TID for behavioral symptoms; lorazepam for acute agitation; clonazepam (dual antimyoclonic and anxiolytic benefit).^[20]
Dysphagia management: Speech therapy consult early; pureed diet, thickened liquids; assess aspiration risk; family education on safe feeding; establish PEG plan before swallowing fails if medication delivery requires it.
Sleep management: Severely disrupted by myoclonus, anxiety, and the disease process itself; melatonin 3–10 mg at bedtime as adjunct; quetiapine has sleep-promoting properties; adequate myoclonus treatment dramatically improves sleep quality.
Terminal phase: Midazolam CSCI 10–30 mg/24h for refractory myoclonus and agitation; glycopyrrolate for secretion management; morphine for dyspnea; akinetic mutism phase requires oral care, pressure care, and family support.

S05Clinician

When Therapy Makes Sense

In prion disease, "therapy" means comfort management — there is no disease-directed treatment. These are the clinical priorities that must be addressed from the first visit to provide adequate comfort management.

In prion disease, every clinical action is a comfort action. The question "when does therapy make sense?" becomes: which comfort interventions are indicated, at which stage, with which priority? The answer must be aggressive from day one — the window for advance directive completion, medication optimization, and family preparation is measured in weeks, not months. Comfort therapy that is deferred is comfort therapy that may never happen.^[19]

01

Aggressive myoclonus management from the day of enrollment: Myoclonus is the dominant comfort problem in CJD and it is undertreated in almost every patient who arrives at hospice enrollment. The patient who arrives with myoclonus rated 8/10 severity on no antiepileptic therapy has not received adequate comfort management. Start clonazepam 0.5–2 mg TID and levetiracetam 500–1000 mg BID at enrollment. Titrate to effect. Do not wait for the myoclonus to become severe before treating — by that point, the patient is in continuous distress and the family is already traumatized by watching it.^[19]
02

Seizure rescue protocol established at enrollment: Post-CJD seizures occur and can be prolonged. Buccal or intranasal midazolam (5–10 mg) for acute seizure rescue must be in the home before any seizure occurs. The family must be trained on administration — not when the seizure is happening, but at the enrollment visit. Include written instructions with the medication. This is a patient safety issue, not an optional clinical consideration.^[21]
03

Anxiety and behavioral symptom management: Early CJD behavioral changes — anxiety, agitation, paranoia, behavioral disinhibition — are among the most distressing symptoms for families and are frequently underestimated by clinicians focused on the neurological picture. Quetiapine 12.5–50 mg TID for behavioral symptoms; lorazepam 0.5–1 mg PRN for acute agitation. Do not under-treat psychiatric symptoms in CJD because "the dementia will get worse anyway." The quality of the time remaining is the clinical target — and a frightened, agitated person in early CJD is suffering in a way that medication can and should address.^[20]
04

Advance directive completion while cognitive capacity persists: This is the most urgent clinical priority in any CJD patient with residual cognitive capacity. The disease progression is faster than any other hospice diagnosis and the window for autonomous decision-making closes in weeks, not months. Complete the advance directive at the first visit that allows it — if the patient can tell you what they want, write it down and have it signed today. The specific questions: intubation for respiratory crisis? PEG tube placement? Antibiotic treatment for aspiration pneumonia? Hospitalization? These decisions must be made before the patient can no longer make them.^[22]
05

Safety protocol education at enrollment: Standard precautions are adequate for home care. The family who believes they can catch CJD by living in the same house as their person is experiencing unnecessary terror that impairs their ability to provide care and to be present. Clear, accurate, compassionate safety education at enrollment removes this fear. WHO transmission risk framework: high-risk tissues are brain, spinal cord, and eyes — these are not contacted in routine home care. Bodily fluids are low-risk. Gloves for blood or wound contact; no special precautions for routine caregiving. Household surfaces and items are safe. This information must be delivered as specific statements, not vague reassurance.^[23]
06

Genetic counseling referral for any familial prion disease: Adult children of a patient with a confirmed or suspected pathogenic PRNP variant require urgent genetic counseling at the first hospice visit — not the second or third. The hospice nurse who facilitates this referral has acted on one of the highest-stakes genetic counseling situations in medicine. Contact the NPDPSC at Case Western Reserve University (1-800-NPDPSC1) for guidance and referral resources. Pre-symptomatic testing for prion disease mutations is available, is a personal decision, and requires genetic counseling support — the hospice team's job is to ensure the referral is made so the family can make an informed choice.^[12]

S06Clinician

When It Doesn't

Interventions that add burden without comfort benefit in confirmed prion disease. Knowing what not to do is as important as knowing what to do — in a disease that moves this fast, every unnecessary intervention takes time and energy that belongs to the family.

In prion disease, the risk of over-intervention is not theoretical. The diagnostic odyssey means many patients arrive at hospice with a long list of medications, scheduled investigations, and procedures initiated during the workup phase. The hospice clinician must review the entire active medication and investigation list at enrollment and ask of each item: does this change a comfort decision? If not, it does not belong in a comfort-focused plan.^[6]

01

Corticosteroids with no clinical benefit in confirmed CJD: Dexamethasone or prednisone initiated empirically during the diagnostic odyssey when autoimmune encephalitis was on the differential should be reassessed at enrollment. If the diagnosis of prion disease is confirmed and no autoimmune process is being treated, the corticosteroid is adding steroid side effects (insomnia, agitation, hyperglycemia, skin fragility, proximal myopathy) without any disease-modifying benefit. Taper and stop with appropriate scheduling. This is one of the most common medication burdens arriving with CJD patients at hospice enrollment.^[24]
02

High-dose antiepileptic escalation beyond comfort doses: The clinical target in CJD is myoclonus comfort and seizure rescue — not EEG-level seizure freedom. Multiple antiepileptic agents at high doses in an end-stage patient with a 4–6 week prognosis add medication burden without proportionate benefit. Clonazepam and levetiracetam at comfort-effective doses address the clinical problem. Adding phenytoin, phenobarbital, or escalating to maximum tolerated doses of multiple agents serves a pharmacological goal that is not aligned with a comfort goal. Escalate to effective comfort, not to maximum tolerable dose.^[25]
03

Nasogastric tube for nutrition in late-stage CJD: In a patient with akinetic mutism and a prognosis of days to weeks, nasogastric tube placement adds procedural burden without comfort benefit. The tube causes nasal and pharyngeal discomfort, increases secretion burden, and does not change the neurological trajectory. Family education about natural end-of-life changes in appetite and nutrition — and the fact that the body at this stage cannot absorb or use nutrition meaningfully — is more helpful than a tube.^[26]
04

PEG tube without explicit values-based indication: The decision to place a PEG tube in a patient with CJD requires explicit clinical framing. The median survival from symptom onset is 4–6 months; the median survival from the time of most PEG decisions in advanced CJD is weeks to a few months at most. A PEG tube does not reverse the neurological trajectory. It does not prevent aspiration of oral secretions. It may provide comfort benefit for medication delivery (especially liquid clonazepam and levetiracetam) in a patient who can no longer swallow pills — which is a specific and legitimate indication. The decision must be explicit, values-based, and not a default. If the patient cannot consent and has no advance directive, the family decision must be framed around comfort, not around nutrition as life prolongation.^[26]
05

CT, MRI, and invasive diagnostic procedures in confirmed CJD: Once prion disease is confirmed, additional imaging and invasive procedures do not change management and add burden. Reassess all scheduled investigations at enrollment and cancel those that cannot change a clinical decision. A follow-up MRI, repeat lumbar puncture, or EEG in a confirmed CJD patient at hospice enrollment contributes nothing to comfort management and requires transportation, facility visits, and procedural stress in a patient who has very little time and capacity remaining.^[6]
06

Hospitalization for fever or aspiration pneumonia in comfort-only patients: Aspiration pneumonia is the most common proximate cause of death in CJD. In a patient who has elected comfort-only care with a documented advance directive, hospitalization for aspiration pneumonia adds institutional distress, separation from family, and procedural burden without changing the trajectory. Home-based management — comfort positioning, oral secretion management, dyspnea management with morphine and midazolam, and family support — is clinically appropriate and ethically preferable. The hospice team must address this specifically before the first episode of fever — not during the acute event when the family may panic and call 911.^[22]

📋 Clinician note: The medication review at enrollment is a clinical obligation

The median CJD patient arrives at hospice enrollment with medications initiated during the diagnostic odyssey that no longer serve a comfort purpose. A systematic review of every medication at the first visit — asking "does this contribute to comfort or does it add burden?" — is one of the highest-value clinical actions in prion disease hospice care. The family who has been dutifully giving seven medications twice daily, some of which are causing side effects that make the patient more uncomfortable, is not helped by continuing those medications out of inertia. Review everything. Stop what does not serve comfort. Explain why.

S07Everyone

Out-of-the-Box Approaches

Evidence-graded clinical strategies for prion disease comfort management that go beyond standard protocols. Grade A = RCT / guideline-level; B = multi-observational / meta-analysis; C = limited clinical, strong expert basis; D = expert opinion / case series.

Clonazepam as Primary Myoclonus Agent

Grade B

Clonazepam 0.5–2 mg TID oral, liquid, or via PEG; titrate to myoclonus comfort

Myoclonus in CJD is caused by cortical and subcortical hyperexcitability from prion-mediated neuronal destruction. Clonazepam — a long-acting benzodiazepine with specific antimyoclonic properties via GABA-A receptor enhancement — is more effective for myoclonic jerks than standard antiepileptics and simultaneously addresses the anxiety and agitation that accompany the myoclonus. The combination of clonazepam plus levetiracetam (which acts through the SV2A synaptic vesicle protein) addresses both myoclonus and seizure risk through complementary mechanisms. The patient with untreated or undertreated myoclonus at CJD hospice enrollment is in continuous neurological distress — disrupted sleep, inability to rest comfortably, exhausting and frightening muscle jerks. Treating it from day one with appropriate doses is among the most impactful comfort interventions in the hospice care of this disease.^[19]

Comfort Sedation Protocol for Refractory Myoclonus & Agitation

Grade B

Midazolam CSCI 10–30 mg/24h via syringe driver or intermittent SQ; titrate to comfort

The refractory myoclonus and agitation of late-stage CJD that does not respond to scheduled clonazepam, levetiracetam, and quetiapine requires continuous subcutaneous midazolam infusion (CSCI). In a disease with no treatment and a prognosis of weeks, the clinical and ethical case for continuous palliative sedation for refractory myoclonic distress and agitation is clear: the patient is suffering continuously, the suffering is refractory to less sedating interventions, and the disease trajectory is known. The family must be prepared for what this level of sedation means — that the patient will be deeply sedated and interaction will be limited — before the CSCI is started. The CSCI protocol must be planned and documented before it is needed. Scrambling to establish CSCI during a myoclonic crisis is avoidable with anticipatory planning.^[27]

Safety Communication Protocol

Grade A

Three specific statements delivered verbally and in writing at the first visit

The single most impactful non-clinical intervention in prion disease hospice is clear, accurate, and compassionate communication of transmission risk. The family who believes CJD is transmitted by casual contact experiences terror about their own safety — terror that impairs caregiving, impairs presence, and compounds grief. WHO and CDC transmission risk frameworks are unambiguous: (1) You cannot get CJD by living in the same home and providing routine care. (2) Standard precautions — gloves when handling blood or open wounds — are all that is required. (3) The home, household items, and bodily fluids in routine contact are not infectious. These three statements must be delivered specifically, not with vague reassurance, and left in writing. A laminated card or printed page with these three statements, kept in the home, is a clinical intervention that removes unnecessary fear and restores the family's ability to be fully present.^[23]

Anticipatory CSCI Planning

Grade B

Document CSCI protocol at enrollment; have midazolam available in the home from week one

In sporadic CJD, the transition from ambulatory to akinetic mutism may occur within 4–8 weeks. The transition from manageable myoclonus to continuous myoclonic distress requiring CSCI may occur within a similar window. Anticipatory planning — documenting the CSCI protocol, prescribing midazolam for home availability, and briefing the family on what CSCI is and when it will be used — before it is urgently needed is the standard of care in CJD hospice. The hospice team that waits until the patient is in continuous myoclonic crisis to begin this process has failed to anticipate a predictable clinical event. Establish the protocol. Have the medication in the home. Explain it to the family before it is used.^[22]

Sensory Comfort Interventions in Akinetic Mutism

Grade D

Music therapy, familiar voice recordings, gentle touch, aromatherapy; individualized to patient history

The patient in akinetic mutism — awake but without purposeful movement or communication — presents an extraordinary challenge for families who do not know whether their person can still perceive what is happening around them. The honest clinical answer is that we do not know with certainty, but the weight of evidence from consciousness research suggests that some level of awareness may persist even without behavioral response. Sensory comfort interventions — preferred music, familiar voices, gentle touch, lavender aromatherapy — carry no risk of harm and may provide meaningful comfort that is not captured by behavioral measures. They also provide the family with something meaningful to do in a situation where they feel helpless, which is itself a comfort intervention for the family. Coordinate with music therapists and chaplains when available.^[28]

Post-Mortem Brain Donation Protocol

Grade A

NPDPSC contact at Case Western Reserve University: 1-800-NPDPSC1; offered at enrollment, not during active dying

Post-mortem brain donation to the National Prion Disease Pathology Surveillance Center provides: (1) definitive histopathological confirmation of diagnosis; (2) subtype classification that is clinically relevant to surviving relatives; (3) contribution to national prion disease surveillance and research; (4) genetic research that may directly benefit adult children who are at risk. Many families who feel helpless in the face of a disease with no treatment find meaning in contributing to research that might protect other families. The conversation about brain donation must be offered — not assumed — and must be offered early enough that the family has time to decide. The NPDPSC provides complete guidance on logistics, including coordination with the funeral home.^[29]

S08Everyone

Natural & Herbal Options

Evidence grading, drug interaction flags, and explicit safety guidance for supplements in prion disease. The primary concern is interaction with clonazepam, levetiracetam, and quetiapine — the core comfort medications.

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"Prion disease has no disease-modifying treatment of any kind — pharmaceutical or herbal. I tell families this directly so they don't spend the weeks they have left chasing a cure in a health food store. What supplements can do is help with specific symptoms: sleep, anxiety, nausea. The question I ask about every supplement in CJD is: does this interact with clonazepam? Because clonazepam is the most important medication we have for myoclonus, and I will not have a family member unknowingly compound a sedating supplement on top of it."

— Waldo, NP · Terminal2

🌿 Clinical Context for Supplements in Prion Disease

Prion disease has no disease-modifying treatment of any kind — pharmaceutical or herbal. The clinical focus is entirely on comfort symptom management. In this context, supplements serve only as adjuncts to comfort — for anxiety, sleep, nausea, or general wellbeing — and must be evaluated only against the active comfort medication regimen. The primary safety concern in supplement selection for prion disease is: does this supplement interact with clonazepam, levetiracetam, or quetiapine? Anything with significant CNS sedation compounds these effects. Anything with seizure threshold-lowering properties is contraindicated. Given the speed of the disease, the practical impact of most supplements is limited — the priority is clarity, brevity, and safety.

Herb / Supplement	Evidence Grade	Typical Dose	Potential Benefit	⚠ Interactions / Contraindications
Melatonin	Grade C	3–10 mg at bedtime; liquid formulation for PEG	Sleep disruption from myoclonus, anxiety, and the disease process itself is severe and early in CJD. Melatonin addresses circadian disruption as an adjunct to scheduled comfort medications. In FFI where insomnia is the dominant symptom, melatonin is insufficient as monotherapy but reasonable as adjunct.^[30]	No significant interaction with clonazepam or levetiracetam at standard doses. Mild additive sedation with quetiapine — monitor. PEG-compatible in liquid formulation. Generally safe in CJD.
Lavender aromatherapy	Grade D	Diffuser in room or topical diluted (2% in carrier oil); used as needed	Anxiety and general distress reduction. May provide sensory comfort for both patient and family. One of the few comfort interventions safely administered to a patient in akinetic mutism — no systemic effect, no swallowing required, no interaction risk.	No drug interaction at aromatherapy doses. No systemic pharmacological effect. Safe for all patients including those with impaired consciousness. Rarely, topical skin sensitivity — use diluted only.
Magnesium (low dose only)	Grade D	Magnesium glycinate 100–200 mg daily; confirm with attending before use	Muscle comfort adjunct. Unlike MG where magnesium is absolutely contraindicated, prion disease does not involve the neuromuscular junction. Low-dose magnesium may provide mild muscle relaxation as adjunct. Evidence in prion disease specifically is absent.	Unlike in myasthenia gravis, neuromuscular junction is not the pathological site in CJD — magnesium is not absolutely contraindicated. However, high doses may impair neuromuscular transmission in debilitated patients. Confirm with attending before initiating. Renal function must be adequate.
Chamomile tea	Grade D	1–2 cups daily as tolerated; avoid in dysphagia — thicken if needed	Mild anxiolytic and calming effect via apigenin binding to GABA-A receptors. Familiar ritual comfort for patients who enjoyed herbal tea before illness. Appropriate early in disease when oral intake is safe.	Mild additive sedation with clonazepam — not clinically significant at usual tea doses. Anticoagulant interaction possible at high supplemental doses — relevant if patient is on anticoagulation for other reasons. Discontinue when swallowing becomes unsafe.
Ginger	Grade D	250 mg capsule or 1 g ginger tea; liquid ginger drops for PEG if tolerated	Nausea reduction. Some CJD patients experience nausea from medications (valproate, levetiracetam). Ginger may provide adjunct antiemetic benefit and is well-tolerated.	Mild antiplatelet activity at high doses — not significant at culinary/low supplemental doses. No interaction with clonazepam or levetiracetam. Safe in CJD. Discontinue if nausea is resolved by medication adjustment.

🚫 Avoid in Prion Disease

St. John's Wort (Hypericum perforatum): Potent CYP3A4 and P-glycoprotein inducer — significantly reduces plasma levels of clonazepam and potentially other CNS medications. In a patient whose myoclonus and seizure control depends on adequate clonazepam levels, St. John's Wort can precipitate loss of seizure and myoclonus control. Avoid completely in CJD patients on clonazepam or levetiracetam.^[31]
Kava (Piper methysticum): Hepatotoxic — serious liver injury risk. CNS depression compounds clonazepam and quetiapine sedation unpredictably. No benefit in prion disease that outweighs these risks. Avoid.
Ginkgo biloba: Antiplatelet effects and proconvulsant potential (lowers seizure threshold at high doses). In a patient at seizure risk from prion disease with cortical hyperexcitability, the proconvulsant risk is not acceptable. Avoid.
Ephedra / ma huang: CNS stimulant — increases agitation and anxiety, which are already dominant and distressing symptoms in early CJD. Proconvulsant. Cardiovascular stimulation. No role in comfort management. Avoid completely.
Cannabis with high THC content: Significant CNS depression compounds clonazepam and quetiapine sedation. High-THC preparations may increase agitation, paranoia, and confusion in neurologically vulnerable patients — these symptoms are already prominent in CJD and are distressing for families. Low-CBD products without significant THC may have less risk but remain unproven in prion disease specifically. If a family insists on using cannabis, provide guidance toward low-THC/moderate-CBD products and document the discussion.

S09Everyone

Timeline Guide

Prion disease has the most compressed disease trajectory in hospice medicine. This is not a guide measured in years — it is measured in weeks. Use it to set expectations, not as a countdown.

Prion disease does not follow the gradual trajectory of most hospice diagnoses. Sporadic CJD — the most common form — has a median survival of 4–6 months from symptom onset, and most patients are already 2–4 months into the disease course before a diagnosis is established. The window from diagnosis to the terminal phase is measured in weeks to a few months, not in the years that most hospice families expect. Familial and variant forms, GSS, and FFI have longer trajectories, but the clinical management principles are the same. Use this timeline to help families understand speed — and to ensure that every clinical priority (advance directives, genetic counseling, myoclonus management, CSCI planning) happens in the window available.^[3]

YRS–
MOS

Pre-Diagnosis / Early Symptoms — Familial & Slower Variants

Applies primarily to familial CJD with known PRNP mutation, GSS (cerebellar ataxia dominant, 2–10 year course), and FFI (progressive insomnia, autonomic dysregulation, early cognitive sparing)
Sporadic CJD patients rarely experience this phase — they arrive at diagnosis already in the middle of their disease course
Early symptoms: subtle cognitive changes, emerging cerebellar signs (gait unsteadiness, coordination difficulties), insomnia in FFI, personality shift — often diagnosed as depression, Alzheimer's, or functional disorder
The diagnostic odyssey begins here: patients are seen by neurologists, psychiatrists, and internists; the average time from first symptoms to diagnosis is 3–5 months
Critical window: advance directive completion, palliative care integration, genetic counseling referral for familial forms — these must happen while the patient can participate
NPDPSC referral (Case Western Reserve University) should be made at diagnosis — surveillance, testing support, and research resources

WKS–
MOS

Rapid Cognitive Decline — Primary CJD Timeline Phase

This is the primary clinical phase for sCJD patients: rapid cognitive decline, disorientation, personality change, behavioral dysregulation (anxiety, agitation, paranoia)
Myoclonus begins appearing — first as subtle startle responses, then as prominent involuntary muscle jerks occurring spontaneously and in response to stimulation
Cerebellar signs: gait ataxia, coordination failure, falls risk increasing
Visual disturbance: diplopia, cortical blindness possible (especially in Heidenhain variant of sCJD)
This phase typically spans 4–8 weeks in sCJD — the family is simultaneously processing the diagnosis, beginning hospice, and watching profound rapid change
Palliative care must be involved immediately at diagnosis — not after months of decline
Advance directive must be completed in this window — decision-making capacity may be lost within 2–4 weeks of diagnosis in rapidly progressing sCJD
Safety conversation with family is a first-visit priority: transmission risk, standard precautions, home safety

DAYS–
WKS

Rapid Deterioration — Active Symptom Management Phase

Severe dementia dominates — disorientation complete, no reliable communication, may not recognize family members
Myoclonus is now dominant and may be near-continuous — bilateral, multifocal, stimulus-sensitive; this is the most distressing visible symptom for families
Dysphagia developing: aspiration risk is rising; oral medication route may be compromised — this is the window to establish PEG or transition to SQ route before it becomes an emergency
Seizures possible: tonic-clonic and focal seizures; rescue medication must be in the home
Behavioral agitation: screaming, thrashing, combative behavior possible in severe cases
Hospice enrollment is most appropriate at this transition if not already enrolled
The entire active symptom management phase of prion disease hospice may span only 2–8 weeks before the terminal phase
CSCI midazolam should be planned and available before continuous myoclonus requires it
This phase is the most clinically demanding — every visit must anticipate the next deterioration

DAYS

Akinetic Mutism — The Most Difficult Phase for Families

Akinetic mutism: the patient is awake — eyes may be open and tracking — but there is no purposeful movement, no verbal response, and no reliable behavioral communication
This is not coma: the reticular activating system is partially intact; the patient may be aware at some level — this is uncertain and cannot be assessed
Families experience akinetic mutism as the most profound and disturbing phase: "She's there but she's not there." This is death before death — and it can last days to weeks
Families must be explicitly prepared for akinetic mutism before it occurs — a family who encounters it without preparation may believe the clinical team has failed or that their person is in a coma
Continue comfort medications: clonazepam and levetiracetam for myoclonus (which may persist), midazolam for refractory agitation, glycopyrrolate for secretions
Myoclonus may continue or increase in this phase despite akinetic mutism — treat aggressively
Family coaching: talk to them, touch them, be present — the value of this does not require certainty about awareness
Hospice chaplain and social worker engagement is essential in this phase for family support

HRS–
DAYS

Final Hours — Active Dying

Breathing changes: Cheyne-Stokes pattern, increasingly irregular respirations, agonal breathing in final hours; mandibular breathing as death approaches
Myoclonus may diminish as neurological depression deepens — or may persist; treat with CSCI midazolam if distressing
Terminal secretions ("death rattle") — glycopyrrolate 0.2 mg SQ q4h or CSCI, reposition to lateral if possible, family education before the sound occurs
Mottling of knees, feet, and hands — educate families that this is circulatory change, not pain; continue comfort medications
Unresponsive but auditory awareness may persist — family should speak to patient, play meaningful music, maintain a calm and loving environment
Seizure risk in final hours: midazolam 5–10 mg SQ drawn and labeled at the bedside; family trained on administration
Call the hospice nurse if: breathing pattern changes dramatically, seizure occurs, family needs support — the on-call nurse should be proactively available in this phase, not waiting to be called
After-death: prion disease-specific considerations for body handling — standard funeral home precautions are adequate; embalming carries small risk from blood exposure — funeral home should be informed of diagnosis; cremation has no transmission risk; autopsy requires specialized pathology protocols and NPDPSC notification

S10Clinician

Medications to Anticipate

Prion disease pharmacology is entirely symptom-directed. There is no disease-modifying medication. Every prescription is a comfort decision.

⚡ Critical Clinical Note: Prion Disease Medication Urgency

Prion disease is among the most rapidly fatal diagnoses in hospice and the medication regimen must reflect this. At enrollment, establish the PEG or SQ plan before the oral route fails — this window closes faster in prion disease than in any other hospice diagnosis. Dysphagia can develop within 2–4 weeks of admission. And establish the continuous SQ infusion (CSCI) protocol for myoclonus before the myoclonus becomes continuous — the time from admission to requiring CSCI is measured in weeks, not months. The patient who arrives at enrollment with 8/10 severity myoclonus on no antiepileptic therapy has not received adequate care before your visit. Fix it at enrollment. Every prescription must balance comfort benefit against the brevity of the remaining time, the speed of cognitive and swallowing decline, and the complexity of managing continuous myoclonus alongside seizure risk, behavioral agitation, and dysphagia.^[22]

Drug	Class / Target Symptom	Starting Dose	Notes / Cautions
Clonazepam	Benzodiazepine / Myoclonus (first-line)	0.5–2 mg PO/PEG TID	The most important comfort medication in CJD. Liquid formulation available for PEG administration. Also addresses anxiety, agitation, and sleep disruption. Titrate to effect — sedation is acceptable and often beneficial. Monitor for respiratory depression in late-stage disease. Compound sedation with other CNS agents must be anticipated and accepted as the clinical target is comfort.^[22]
Levetiracetam	Antiepileptic / Myoclonus + Seizure	500–1000 mg PO/PEG/IV BID	Adjunct to clonazepam for combined antiepileptic and antimyoclonic effect. Liquid formulation for PEG; IV if PEG unavailable. Renally adjusted — check GFR at enrollment. One of the most important dual-purpose medications in prion disease hospice — addresses both myoclonus and seizure prophylaxis with a single agent. Fewer sedation and interaction concerns than valproate.^[23] Preferred over valproate in most CJD patients due to simpler monitoring requirements in this population.
Midazolam SQ	Benzodiazepine / Acute Seizure Rescue + CSCI for Refractory Myoclonus / Terminal Agitation	5–10 mg SQ acute; CSCI 10–30 mg/24h	Must be in the home from day one of enrollment — drawn and labeled for acute seizure use. CSCI established before the terminal phase to avoid scrambling in a myoclonic crisis. Titrate CSCI upward in 30% increments if myoclonus or agitation continues. Compatible with glycopyrrolate in same syringe driver in most formulations — verify with pharmacy.^[24] The most versatile and critical rescue medication in CJD hospice. Have it available, labeled, and family trained on use before it is needed.
Quetiapine	Atypical Antipsychotic / Behavioral Symptoms	12.5–50 mg PO/PEG TID	For early CJD behavioral symptoms: anxiety, agitation, paranoia, behavioral disinhibition. Lower doses (12.5–25 mg) are often effective. Via PEG as tablets crushed or liquid where available. Do not use haloperidol as first-line for behavioral symptoms in CJD — quetiapine's broader receptor profile is better suited to the neuropsychiatric complexity of CJD. Transition to haloperidol SQ in late stage if PEG unavailable.^[7] ⚠ Caution: QTc prolongation — verify ECG if clinical concern; avoid in patients on QTc-prolonging agents.
Morphine	Opioid / Pain + Dyspnea	2.5–5 mg PO/SQ q4h PRN	Pain is not always a dominant symptom in CJD, but dyspnea may emerge in later stages. Morphine is appropriate for dyspnea management in the preterminal and terminal phases. SQ route as oral route fails. Do not withhold opioids in CJD for fear of respiratory depression — comfort is the clinical target.^[25]
Lorazepam	Benzodiazepine / Anxiety	0.5–1 mg PO/SQ q4–6h PRN	For acute anxiety episodes not controlled by scheduled clonazepam. Useful as PRN bridge while titrating clonazepam dose. SQ route as oral route fails. Avoid scheduled use unless breakthrough is very frequent — clonazepam's TID schedule provides better baseline coverage.
Haloperidol	Antipsychotic / Agitation + Delirium (late stage)	0.5–2 mg PO/SQ q4–8h	Preferred agent for late-stage agitation and delirium when PEG is unavailable and SQ route is required. Also compatible in CSCI with midazolam and morphine — verify compatibility with pharmacy. CSCI dose 2.5–10 mg/24h for continuous agitation management. Not first-line for early behavioral symptoms (prefer quetiapine).^[26]
Glycopyrrolate	Anticholinergic / Terminal Secretions	0.2 mg SQ q4h; CSCI 0.6–1.2 mg/24h	Preferred over hyoscine in any patient who may have residual awareness — glycopyrrolate does not cross the blood-brain barrier and has no CNS sedating effects. Reduces secretion volume; cannot clear secretions already present. Repositioning and gentle suctioning as adjuncts. Family education before terminal secretions begin: the sound is not distressing to the patient.^[27]
Hyoscine butylbromide	Anticholinergic / Secretions (alternative)	20 mg SQ q4h; CSCI 60–120 mg/24h	Alternative to glycopyrrolate where unavailable. Does not cross blood-brain barrier in standard doses. Available in many community palliative care settings. Compatible with midazolam and haloperidol in syringe driver — verify locally. Use when glycopyrrolate is not available.
Dexamethasone	Corticosteroid / Empiric (taper and stop)	Taper to zero — do not continue	⚠ Dexamethasone that was initiated empirically during the diagnostic workup (for presumed autoimmune encephalitis or cerebral edema) should be tapered and stopped at hospice enrollment if CJD diagnosis is confirmed and no autoimmune process is being treated. Continuing steroids in confirmed CJD adds side effects (hyperglycemia, immunosuppression, agitation, myopathy, fluid retention) without any disease-modifying benefit. Taper to zero over 1–2 weeks depending on duration of prior use.^[7]

🌿 CJD Symptom Management Decision Tree

Prion Disease · Evidence-based · Hospice-adapted

Select a symptom below to begin

What is the primary symptom to address?

🚨 CJD Comfort Kit — Must-Haves at Every Home Visit

Midazolam 5–10 mg SQ — drawn and labeled: For acute seizure rescue. Family must know where it is and how to use it before any seizure occurs. Train at enrollment.
Midazolam CSCI protocol documented and available: 10–30 mg/24h for continuous refractory myoclonus or terminal agitation. Have the prescription ready before the crisis.
Clonazepam liquid via PEG: Ensure PEG formulation or liquid compounding is ordered before the tablet route fails. The window closes fast.
Glycopyrrolate 0.2 mg SQ — drawn and labeled: For terminal secretions. Teach the family that secretion sounds do not mean the patient is suffering before the sound begins.
Haloperidol 0.5–1 mg SQ: For late-stage agitation and delirium when PEG is unavailable.
Route transition plan in writing: Document the plan for transitioning from oral to PEG to SQ at enrollment — do not leave this to be improvised when the patient can no longer swallow.

S11Clinician

Clinician Pointers

High-yield clinical pearls for the hospice team managing prion disease. The things not in the textbook — learned at the bedside in the most compressed and devastating disease trajectory in palliative medicine.

1

The safety conversation must happen at the first visit — with three specific statements, in writing

The family of a CJD patient needs to hear three specific statements, and vague reassurance is not enough: (1) "You cannot catch CJD by living in the same house and providing routine care." (2) "Standard precautions — gloves when handling blood or open wounds — are all that is required." (3) "The home does not need to be decontaminated and your personal items are not infectious." Write these statements on paper. Leave the paper in the home. The family who has been given vague reassurance without specific language will fill the information vacuum with fear — and that fear will prevent them from being physically present with their person at the end of their life. The WHO transmission risk framework is the source: high-risk tissues are brain, spinal cord, and eyes; blood and CSF carry very low risk; routine contact and household exposure carry no documented risk.^[28]

2

Advance directive completion is a first-visit obligation — not a second-visit priority

In CJD, the window for autonomous decision-making may close in weeks. The disease progression eliminates decision-making capacity faster than any other hospice diagnosis. At the first visit with a cognitively capable CJD patient, the advance directive conversation must happen. If the patient can tell you what they want, write it down and have it signed today. The specific questions for CJD: Do you want intubation for a respiratory crisis? Do you want a PEG tube placed? Do you want antibiotics for aspiration pneumonia? Do you want hospitalization? Do you want CPR? A completed advance directive at the first cognitively capable visit is not optional in prion disease — it is the most important clinical act of the enrollment visit. When capacity is lost — and it will be lost — the family needs paper with the patient's voice on it.^[29]

3

Genetic counseling referral for familial prion disease is a clinical obligation at enrollment

If the patient has a confirmed or suspected pathogenic PRNP mutation, the adult children of this patient have a 50% chance of having inherited a mutation with near-100% lifetime penetrance for a uniformly fatal neurological disease. This is the highest-stakes genetic counseling situation in all of palliative medicine. The hospice nurse who facilitates the genetic counseling referral at enrollment has potentially saved lives. Contact the National Prion Disease Pathology Surveillance Center (NPDPSC) at Case Western Reserve University — (216) 368-0587 — for guidance and referral resources. The referral takes a phone call. The consequences of not making it cannot be undone.^[30]

4

Prepare families for akinetic mutism before it occurs — explicitly and in detail

Akinetic mutism is the phase of CJD that is most devastating for families because it looks like coma but isn't, and it can last days to weeks. The patient has eyes that may be open and tracking; there are no purposeful movements; there is no verbal response. Families who encounter this phase without preparation believe they are watching something go wrong — a medication failure, a clinical error, a coma. Prepare them in the week before this phase arrives with specific language: "There's a phase coming that's very common in this disease. Your person's eyes may be open and they may seem to be awake, but they won't be responding. This isn't a coma — it's the disease affecting the parts of the brain that allow purposeful movement and speech. We believe it's possible they can still hear. Keep talking to them. Keep touching them. Keep your voice calm. The comfort medications are still working and we will not stop them." This preparation prevents a family from experiencing this phase as abandonment or failure.^[31]

5

Myoclonus assessment and treatment from day one — it is almost always undertreated at enrollment

Myoclonus is the dominant comfort problem in CJD and it is undertreated at hospice enrollment in the vast majority of cases. Patients arrive on no antiepileptic therapy, or on a single subtherapeutic dose of levetiracetam, with myoclonus rated 7–9/10 severity. The correct treatment from day one is: clonazepam 0.5–2 mg TID as the primary antimyoclonic agent (more effective than standard antiepileptics for myoclonic jerks specifically), combined with levetiracetam 500–1000 mg BID for dual antiepileptic and antimyoclonic coverage. Assess myoclonus severity at every visit. Titrate aggressively toward comfort — the clinical target is not EEG-level seizure freedom, it is the patient's freedom from distressing muscle jerks. Document severity, frequency, and impact on sleep and positioning at every visit.^[22]

6

Plan the CSCI midazolam protocol before it is needed — not during the myoclonic crisis

Continuous subcutaneous infusion (CSCI) of midazolam for refractory myoclonus and agitation is a clinical inevitability in most CJD patients. The transition from intermittent SQ rescue to continuous infusion happens rapidly when myoclonus becomes continuous or when the patient is using more than 3 rescue doses per 24 hours. Plan for this at enrollment: document the CSCI protocol in the care plan, have the prescription written, have the medication available, ensure the on-call nurse knows the protocol, and brief the family on what CSCI means and what it will look like before it is started. Starting a CSCI midazolam infusion in the middle of a myoclonic crisis, scrambling for the right orders and medication and equipment at 2 AM, is a failure of anticipatory planning. The dose range is 10–30 mg/24h — start at 10–15 mg/24h and titrate up in 30% increments to effect.^[24]

7

Post-mortem brain donation and NPDPSC contact — bring it up at enrollment, not just at death

Brain donation after death serves two purposes in prion disease: it provides the definitive pathological confirmation of diagnosis and prion strain (which has implications for surviving family members with potential genetic risk), and it contributes to the surveillance and research that is the only path toward a future treatment. The NPDPSC at Case Western Reserve University coordinates post-mortem brain examination for prion disease cases — (216) 368-0587. The autopsy protocol requires specific tissue handling procedures that the pathology team must be briefed on. Families should be offered this option at enrollment, not only at the time of death when they are in acute grief and may not be able to process the conversation. Most families who are informed of the research implications say yes. Those who say no should be respected without pressure.^[30]

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"Every CJD patient I've seen has arrived on my caseload undertreated for myoclonus. Every single one. The family is watching their person jerk and shake every few minutes, all day and all night, and nobody has prescribed adequate clonazepam. That is the thing I fix in the first hour of the first visit. After that, everything else is possible."

— Waldo, NP · Terminal2

S12EveryoneClinician

Psychosocial & Spiritual Care

The psychological devastation of prion disease is proportional to its speed. Families who should have had years are given weeks. This section addresses the specific grief architecture of CJD.

Psychosocial distress in prion disease is not merely the normal grief of terminal illness — it is a qualitatively different experience compressed into a timeline so short that the normal psychological mechanisms of adjustment cannot fully engage. The family of a CJD patient is not adjusting to a terminal diagnosis over months or years. They are being asked to process diagnosis, functional decline, cognitive loss, personality dissolution, akinetic mutism, and death — often within the span of 8–16 weeks. The hospice clinician who treats CJD psychosocial care as interchangeable with other diagnoses has not understood what is happening to this family.^[32]

Your job in psychosocial care for CJD is to name what is happening explicitly. The speed, the ambush quality, the diagnostic odyssey that preceded diagnosis, the transmission fear, the genetic burden for surviving children — each of these is a specific psychological wound that requires specific acknowledgment. Generic platitudes will not reach this family. Specific, honest, grounded language will.

Psychological Distress Screening

Depression & Anxiety — Screen at Every Visit

Grade B

In CJD, depression and anxiety are highly prevalent in the early phase when the patient still has cognitive capacity — the combination of receiving a fatal diagnosis with no treatment, watching one's own cognitive disintegration, and knowing that the time from now to death may be weeks creates an anxiety and depression burden that is acute and requires treatment.

Single-question screen: "Are you depressed?" has 100% sensitivity in terminally ill populations when phrased directly. Use it at every capable visit.
PHQ-2: "Little interest/pleasure" + "Feeling down/hopeless" — score ≥3 warrants further assessment and treatment
Mirtazapine 7.5–15 mg QHS: First-line in hospice for depression — also addresses insomnia and anorexia; faster onset than SSRIs; relevant in CJD where time is short
Clonazepam TID: addresses both myoclonus and anxiety simultaneously — the treatment for anxiety in CJD overlaps with the treatment for myoclonus in a clinically useful way
Distinguish depression from appropriate sadness about prion disease — both deserve attention; pharmacotherapy is indicated when depression reaches clinical threshold and time remains for benefit

Speed and Grief Compression — The Defining Psychosocial Feature of CJD

Expert

Name it explicitly: "In most of the diseases I work with, families have time to adjust gradually. In prion disease, you don't get that time. The grief that usually takes years is happening in weeks. That is a specific kind of devastation and I want to acknowledge it directly."
The compressed grief of prion disease is not just faster — it is qualitatively different. The family cannot habituate to decline because decline outpaces adaptation. Each visit reveals a new loss before the previous one has been processed.
Anticipatory grief — the grief for what is being lost before death — is maximally compressed. The spouse who is losing their partner's personality, cognition, and communication simultaneously, in weeks, is experiencing multiple losses at once.
Refer to social work and chaplain at enrollment — not at crisis. Grief support begins on day one of hospice, not at end-of-life.

Prion Disease-Specific Psychological Burdens

The Diagnostic Odyssey — Grief Before the Diagnosis

Most CJD patients have spent 3–5 months being seen by multiple specialists before the diagnosis was made — during which time they may have received diagnoses of depression, Alzheimer's disease, Lyme disease, autoimmune encephalitis, vitamin deficiency, or functional neurological disorder. The family watched their person being evaluated for treatable conditions and felt the hope of each possible diagnosis, then watched that hope extinguished when prion disease was finally named.

The anger and grief about this diagnostic delay is legitimate and often profound. Acknowledge it directly: "You spent months waiting for an answer that turned out to be the worst possible answer. That is a specific kind of trauma. The time you spent hoping for something treatable was not wasted — it was reasonable, and it makes the diagnosis harder, not easier."

Transmission Fear and Its Impact on Caregiving

The fear of catching CJD is the most preventable source of psychological harm in prion disease caregiving. Family members who believe they might contract CJD by touching their person, sleeping in the same bed, or preparing their person's food will maintain physical distance at the end of life — creating a profound and preventable source of complicated grief.

Accurate safety communication removes this fear. The family who has been told specifically and in writing that routine care poses no transmission risk can be physically present without fear. The family who has not been told this will grieve, after their person dies, the physical distance they maintained out of terror that was entirely preventable with a five-minute conversation.

Give them the specific statements. Write them down. Leave the paper.

Genetic Testing Burden — The 50% Inheritance Shadow

In familial prion disease with a confirmed pathogenic PRNP mutation, adult children of the affected patient face a 50% probability of having inherited a mutation with near-100% lifetime penetrance. The psychological burden of this knowledge — or of not knowing — is substantial and requires sensitive, expert handling.

The hospice team's role is not to counsel adult children directly on genetic testing decisions, but to: (1) ensure the genetic counseling referral is made; (2) acknowledge the burden explicitly to the family; (3) not minimize it by rushing past it; and (4) make clear that predictive genetic testing is available, is a choice — not an obligation — and that support services exist regardless of what they decide.

Some adult children will want to know. Some will not. Both decisions are valid and both deserve support without pressure.

Goals-of-Care Communication Adapted for Prion Disease Speed

Time-compressed goals discussion: Prognosis disclosure must be faster and more direct in CJD than in other hospice diagnoses — the window for autonomous decision-making is measured in weeks, not months
"What is your understanding of where things stand?" — assess understanding before adding information
"Given the speed of this disease, what matters most to you in the time you have?" — elicits priorities explicitly
"Is there anything that must happen before things get worse?" — surfaces unfinished business and time-sensitive priorities
Do not use language of surrender. "Shifting the focus of care" — not "stopping treatment." There is always more to do.
Have this conversation sitting down. In a chair. Not standing in a doorway. The patient will fill the silence if you leave it.

Spiritual Assessment

Prion disease has a specific spiritual dimension that differs from other terminal diagnoses: the speed of cognitive dissolution means that the patient may lose the capacity for spiritual expression very early. The hospice chaplain's window to work with the patient directly may be weeks. Use the FICA framework (Faith/beliefs, Importance, Community, Address) at the first capable visit — not the third. The question "What gives you strength right now?" is both assessment and intervention. For the patient who has no religious affiliation, "What feels meaningful to you about the time you have left?" opens the same space.^[33]

Clinical Pearl — Compressed Spiritual Window

"The chaplain needs to see the CJD patient at the first visit, not after the social worker has made the referral and scheduled in two weeks. The patient who is cognitively accessible at enrollment may not be accessible in a month. The spiritual care that can happen in the first two weeks of hospice is infinitely more than the spiritual care that can happen at akinetic mutism. Don't wait for the right moment — there may not be another one."

01
Involve chaplaincy at enrollment — first visit, not first crisis: Spiritual care is the clinical discipline of the chaplain. The hospice nurse's job is to open the door at enrollment, not to wait for the family to ask.^[33]
02
Legacy and meaning work — done early while patient can participate: "What do you most want your family to remember about you?" is both assessment and intervention. In CJD this question must be asked while the patient can answer it. This is not a nice-to-have — it is time-sensitive.
03
Acknowledge unfinished business explicitly: Relationship ruptures, things left unsaid, milestones that won't happen — in a disease this fast, there is rarely time to fully address these, and the family knows it. Acknowledge that the disease is faster than the grief. That is a specific kind of tragedy.
04
Family spiritual support must continue after the patient loses capacity: The chaplain's work with the family in the akinetic mutism phase and after death is as important as the work with the patient during the early phase. Bereavement support should be initiated before death, not after.

Suicidal Ideation & Hastened Death Requests

Passive wish for death ("I'm ready to go — I don't want to go through this disease") is common in newly diagnosed CJD patients and often existentially appropriate given the prognosis. It is not the same as active suicidal ideation. In a disease with no treatment and weeks to months of prognosis, many patients rationally wish the disease would progress faster. Assessment requires careful clinical distinction: passive wish for death (common, often appropriate in context), active suicidal ideation with plan (requires immediate engagement and safety planning), and medical aid in dying requests (legal in some jurisdictions — requires specific protocol; CJD's cognitive decline trajectory creates complex questions about decision-making capacity that require expert consultation). Do not avoid the question. "Are you thinking about ending your life sooner?" asked directly, with compassion, opens a conversation that the patient may be desperate to have with someone who won't panic.^[34]

From the Field

Waldo Rios, NP

Hospice NP · 12+ Years

"The spouse of a CJD patient told me she felt like she was being robbed in slow motion — not slow enough to get used to, fast enough to be constantly blindsided. She didn't need me to fix that. She needed me to say: 'You are right. This is a robbery. And I'm going to be here with you every step of it.' That's psychosocial care in CJD. You don't have months to build trust. You have the first visit."

— Waldo, NP · Terminal2

S13FamilyEveryone

Family Guide

Plain language for the families of people with prion disease. Share, print, or read aloud at the bedside.

Prion disease moves faster than any other disease we work with in hospice. What you are watching — the changes week to week, the muscle jerks, the confusion that arrived and deepened so quickly — is not a sign that something went wrong with your person's care. It is the nature of this illness. There is no treatment that slows it, and there is no clinical mistake that caused it to move this fast. What we can do — what we will do together — is make sure that every day that remains is as comfortable and present as possible. Your presence beside them is the most powerful comfort we have. This guide is to help you understand what you may see, and exactly how you can help.

Próximamente en español. — Coming soon in Spanish.

🛡 Safety — Please Read This Carefully

You cannot get prion disease by living in the same home as your person. You cannot get it by touching them, hugging them, kissing them, sharing meals, or breathing the same air. You do not need to wear protective equipment beyond what you would use for any other person — gloves when you handle blood or open wounds, which is standard for anyone.

Your home does not need to be cleaned with special products. Your dishes, your laundry, your furniture — none of these are infectious. The only tissues that carry meaningful transmission risk are brain tissue and spinal cord tissue, and you will not encounter those in routine home care. The World Health Organization, the CDC, and the published medical evidence are clear on this: there is no documented case of CJD transmitted by household or routine caregiver contact.

Please do not let fear keep you from being present with your person. They need you there. The presence of the people they love is a comfort that no medication can replace.

What You May See

Rapid changes day to day or week to week: This disease moves faster than almost any other. Changes that would take years in Alzheimer's may happen in weeks. This is the nature of prion disease — not a sign that something went wrong with the care.
Sudden muscle jerks or twitching (myoclonus): Involuntary muscle movements that your person cannot control, often worse with sudden noise or touch. There is medication that significantly reduces these — your nurse will make sure they are managed. Call if they are constant, distressing, or causing injury.
Increasing difficulty with speech and swallowing: Your person may lose the ability to communicate clearly or may stop speaking. Swallowing may become unsafe. Your nurse will help you understand what is safe to offer by mouth and when to stop.
A phase when eyes are open but there is no response (akinetic mutism): This is not a coma. Your person may be aware at some level — we cannot know for certain. This is the disease affecting the parts of the brain that control purposeful movement and speech. Continue to speak to them, touch them, and be present. The comfort medications are still working.
Behavioral changes — agitation, anxiety, unusual behavior: These are neurological symptoms caused by the disease. There is medication that helps significantly. Report these to your nurse immediately — they are treatable and they do not have to be this bad.
Increasing sleepiness and withdrawal: The disease is progressing. Rest is appropriate and expected. Your presence beside them while they sleep is meaningful.

How You Can Help

Be present without needing to fix things: You cannot fix this disease. But you can be there. The sound of your voice, the touch of your hand, your presence in the room — these are real comfort, not wishful thinking. Studies show that patients in the presence of people they love have less pain behavior and better comfort markers. Be there.
Report myoclonus immediately: If the muscle jerks are getting worse, more frequent, or causing your person visible distress, call the nurse. There is medication available and the nurse can adjust it. You do not have to watch your person jerk continuously while waiting for the next scheduled visit.
Mouth care: When swallowing becomes unsafe, keep the mouth moist with small swabs and clean water. Dry mouth is uncomfortable. You can keep the lips moistened with a lip balm and offer small ice chips if safe. Your nurse will show you how.
Talk to them even during the unresponsive phase: In the phase when your person is not responding, continue to speak to them. Tell them they are loved. Tell them who is in the room. Play music that mattered to them. We believe hearing may persist when purposeful response has stopped.
Take care of yourself: You are under an extraordinary level of stress in an extraordinarily short period of time. You cannot pour from an empty cup. Call us when you need support — not just when the patient does. Sleep when you can. Accept help when it is offered. Your grief is real and it started before the death.
Ask your nurse to leave instructions in writing: Ask for written instructions for every medication and every emergency sign. When you are exhausted and frightened, you need written instructions — not memory.

📞 Call the Nurse Immediately If You See:

A seizure (shaking of the whole body, eyes rolling, unresponsive for more than 30 seconds) — use the rescue medication your nurse has shown you how to use; call the hospice line immediately. | Myoclonus that is continuous, distressing, or causing injury — this is manageable; call now, not at the next scheduled visit. | Breathing that becomes very labored, very rapid, or stops for long periods — call immediately. | Sudden inability to swallow that you were not told to expect — do not give medications or fluids by mouth; call the nurse. | Severe agitation, screaming, or distress that does not respond to comfort measures — there is medication for this; call immediately. | You are afraid, overwhelmed, or unsure about anything — this is also a reason to call. You do not have to reach a threshold of emergency to call us. We are here.

🙏 Families who are present at the end of a life with prion disease carry something that matters beyond measure: the knowledge that they did not let fear keep them away; that they were there; that their person heard their voice and felt their touch. The disease was fast and brutal. Your love was consistent and present. That is not a small thing. That is everything.

S14Everyone

Waldo's Top 10 Tips

Twelve years at the bedside of dying people. These are the things that CJD taught me that no textbook did. Not guidelines — real.

01

The safety conversation must happen at the first visit with complete specificity — not vague reassurance, but three specific statements written on paper and left in the home. You cannot catch CJD from routine care. Standard precautions — gloves for blood and wounds — are all that is required. The home is safe. These are not reassurances. They are clinical facts from the WHO transmission risk framework, and they need to be delivered as facts — not hedged, not softened, not buried in qualifications. The family who leaves the first visit without this information will fill the vacuum with terror. That terror will keep them physically apart from their dying person. And that distance — that fear-driven distance — will become a source of grief they carry for the rest of their lives. Give them the paper. Leave it on the table. The safety conversation is the most important clinical act of the first visit.
02

Advance directive completion is a first-visit obligation in CJD — not a second-visit priority, not something to get to once you've built rapport. The window for autonomous decision-making in sporadic CJD may close in 2–4 weeks from enrollment. If the patient can communicate today, the advance directive conversation happens today. The specific questions for CJD that must be answered while they can answer them: Do you want to be intubated if you stop breathing? Do you want a PEG tube? Do you want antibiotics for pneumonia? Do you want hospitalization? Do you want CPR? These questions need answers on paper with a signature today, because in three weeks there may be no one there to answer them. The family who has the patient's voice in writing is infinitely more able to advocate for the right decisions in the final weeks. The family without it is making guesses in a crisis. Do not leave the first cognitively capable visit without a completed or in-progress advance directive.
03

Myoclonus is the dominant comfort problem in CJD and it is almost always undertreated at hospice enrollment. I have not seen a CJD patient who arrived at my caseload with adequate myoclonus management. Not one. They arrive with no antiepileptic therapy, or with a single inadequate dose of levetiracetam, while the family watches their person jerk every 30 seconds all day and all night. The correct treatment from day one is clonazepam 0.5–2 mg TID as the primary antimyoclonic agent — it is more effective for myoclonic jerks than standard antiepileptics — combined with levetiracetam 500–1000 mg BID for dual antiepileptic and antimyoclonic coverage. Start at enrollment. Titrate aggressively toward comfort. The patient with 8/10 severity myoclonus on no treatment has not received adequate care before your visit. Fix it in the first hour. After that, everything else is possible. You can teach presence and you can teach courage and you can teach comfort care — but you cannot teach any of it if the patient and family are being traumatized by continuous myoclonus that nobody treated.
04

The advance to CSCI midazolam for continuous myoclonus and agitation is a clinical inevitability in most CJD patients and must be planned before it is needed — not during the myoclonic crisis at 2 AM. The transition from intermittent SQ rescue to continuous infusion happens rapidly when myoclonus becomes continuous. Plan for it at enrollment. Document the CSCI protocol in the care plan. Have the prescription written and the medication available. Brief the on-call nurse on the protocol. Brief the family on what a CSCI infusion looks like and what it means before you start it — because starting a continuous sedation infusion in a patient with CJD who is actively in a myoclonic crisis, without the family being prepared for what they're about to see, is a clinical failure on top of a crisis. CSCI midazolam starting dose is 10–15 mg/24h, titrated upward in 30% increments to effect. Haloperidol can be added to the same syringe driver for concurrent agitation — verify compatibility with your pharmacy. Plan this. Don't scramble.
05

Familial prion disease requires genetic counseling referral at the first hospice visit without exception — no delay, no waiting for a better moment, no deferring until the family asks. If the patient has a confirmed pathogenic PRNP mutation — E200K, D178N, P102L, or any documented pathogenic variant — the adult children of this patient have a 50% chance of having inherited a mutation with near-100% lifetime penetrance for a uniformly fatal neurological disease. This is not an ancillary concern. This is one of the highest-stakes genetic counseling situations in all of medicine, and the hospice nurse who facilitates the referral has potentially saved lives. Call the NPDPSC at Case Western Reserve University: (216) 368-0587. They have resources, guidance, and referral networks. The referral takes a phone call. Make it at enrollment. The consequences of not making it — adult children who could have been tested, who could have made informed decisions about their future, who could have accessed research protocols — cannot be undone after the patient dies.
06

The akinetic mutism phase will arrive, and it will devastate the family if they are not prepared for it. This is your job — to prepare them in the week before it happens, with specific language that makes it comprehensible rather than terrifying. The patient in akinetic mutism has eyes that may be open and tracking. There are no purposeful movements. There is no verbal response. The family sees someone who looks awake but gives nothing back, and without preparation, this looks like abandonment — like the disease has taken their person and left a shell that looks like them. Prepare them: "There's a phase coming that's very common in this disease. Your person's eyes may be open and they may seem awake, but they won't be responding. This isn't a coma — it's the disease affecting the parts of the brain that allow purposeful movement and speech. We believe it's possible they can still hear. Talk to them. Touch them. Say what you need to say. The comfort medications are still working and we're not going to stop them." This five-minute conversation, given a week before the phase arrives, makes the phase survivable. Without it, families experience akinetic mutism as the moment they lost their person — and carry that experience as the defining image of the death.
07

Post-mortem brain donation is a conversation that belongs at enrollment — not at death. The family at the bedside of an actively dying CJD patient cannot process a conversation about autopsy and research participation. The family at enrollment can. Brain donation in prion disease serves two purposes: it provides the definitive pathological confirmation of the diagnosis and prion strain — which has direct implications for genetic risk assessment in surviving family members — and it contributes to the surveillance and research infrastructure that is the only path toward a future treatment for this disease. Most families who are informed of these implications say yes. Give them the information at enrollment. Contact the NPDPSC at Case Western Reserve University to coordinate — (216) 368-0587. They will guide the family, the funeral home, and the pathology team through the process. Families who participated in brain donation programs have told me, in bereavement, that it was the one thing they could do. In a disease where everything else was beyond their control, this was something they could give. Offer it. Let them decide.
08

The diagnostic odyssey that precedes every CJD diagnosis is a specific trauma that must be acknowledged, not bypassed. The average patient with CJD has spent 3–5 months being evaluated by multiple specialists before the diagnosis was established. In those months, they may have been diagnosed with depression, early Alzheimer's, autoimmune encephalitis, Lyme disease, vitamin deficiency, thyroid disease, or functional neurological disorder. The family felt the hope of each possible treatable diagnosis, and then watched that hope disappear when prion disease was finally named. The anger and grief about this is legitimate, and it is sitting in the room with you at every visit. Name it. "You spent months waiting for an answer, and the answer turned out to be the worst possible one. The time you spent hoping for something treatable was not wasted time — it was reasonable medical evaluation, and you were right to hope. But I understand that it makes the diagnosis harder, not easier, to have hoped that hard." This is not processing you need to complete. It is a name you need to give. Families who have the experience named feel less alone in it.
09

The caregiver burden profile in CJD is extreme and acute — the caregiver is compressed through months of physical and psychological caregiving into weeks, with no time for rest, adjustment, or reinforcement. Research on CJD caregivers documents severe sleep disruption from myoclonus (which disrupts sleep for everyone in the home), high rates of acute stress response, and profound anticipatory grief that is qualitatively different from the grief in longer disease trajectories. What you watch for: the caregiver who says "I'm fine" at every visit while looking hollowed out; the spouse who hasn't slept more than three hours in a row in two weeks; the adult child who is managing full-time caregiving while maintaining a job because there is no one else. What you do: ask directly — "How are you sleeping? When did you last eat a real meal? Who is helping you?" Activate respite services at enrollment. Involve social work at enrollment. The caregiver who collapses at week six of a CJD hospice has not been adequately supported by the clinical team. Watch for it. Act on it.
10

In prion disease, presence is the intervention. There is no treatment to slow the disease. There is no procedure that will buy time. There is no medication that will restore who this person was. But there is presence — the hospice nurse who shows up at the door with clinical precision and human warmth; the chaplain who sits down and says nothing, then says the right thing; the social worker who calls the caregiver at 7 PM to see how the day went. What families of CJD patients remember is not whether the myoclonus was perfectly controlled (though it should be) or whether the advance directive was completed on the right day (though it should be). What they remember is who showed up. Who was honest. Who didn't flinch at the word prion disease or retreat into clinical distance when the disease was moving too fast to keep up with. The speed of prion disease means that every visit is a last visit for something — the last time the patient can speak, the last time they can answer a question, the last time they know their family's names. Show up knowing that. Be present with what's still possible. Say what needs to be said. Don't wait for the right moment — there may not be another one.

— Waldo, NP

REFClinician

References

Peer-reviewed citations supporting all 14 sections. Evidence levels assigned by article type. PMIDs hyperlinked where known.

1

Centers for Disease Control and Prevention. Creutzfeldt-Jakob Disease, Classic (CJD): Occurrence and Transmission. CDC.gov. Updated 2023.

cdc.gov/prionsSurveillance

2

Parchi P, Giese A, Capellari S, et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol. 1999;46(2):224–233.

PMID 10443887Observational

3

Pocchiari M, Puopolo M, Croes EA, et al. Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. Brain. 2004;127(Pt 10):2348–2359.

PMID 15342360Observational

4

Zerr I, Kallenberg K, Summers DM, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain. 2009;132(Pt 10):2659–2668.

PMID 19773352Observational

5

Foutz A, Appleby BS, Hamlin C, et al. Diagnostic and prognostic value of human prion detection in cerebrospinal fluid. Ann Neurol. 2017;81(1):79–92.

PMID 27893164Observational

6

McGuire LI, Peden AH, Orrú CD, et al. Real time quaking-induced conversion analysis of cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease. Ann Neurol. 2012;72(2):278–285.

PMID 22926858Observational

7

Geschwind MD. Prion diseases. Continuum (Minneap Minn). 2015;21(6 Neuroinfectious Disease):1612–1638.

PMID 26633779Review

8

Vitali P, Maccagnano E, Caverzasi E, et al. Diffusion-weighted MRI hyperintensity patterns differentiate CJD from other rapid dementias. Neurology. 2011;76(20):1711–1719.

PMID 21576695Observational

9

Steinhoff BJ, Zerr I, Glatting M, et al. Diagnostic value of periodic complexes in Creutzfeldt-Jakob disease. Ann Neurol. 2004;56(5):702–708.

PMID 15468074Observational

10

Mead S, Khalili-Shirazi A, Potter C, et al. Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldt-Jakob disease: evaluation of a first-in-human treatment programme. Lancet Neurol. 2022;21(4):342–354.

PMID 35334234Clinical Trial

11

World Health Organization. WHO Infection Control Guidelines for Transmissible Spongiform Encephalopathies. WHO/CDS/CSR/APH/2000.3. Geneva: WHO; 2000.

WHO PublicationGuideline

12

Rutala WA, Weber DJ; Healthcare Infection Control Practices Advisory Committee (HICPAC). Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008. Updated 2019. CDC/HICPAC. 2008/2019.

CDC/HICPAC GuidelineGuideline

13

Brown P, Preece M, Brandel JP, et al. Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology. 2000;55(8):1075–1081.

PMID 11071481Review

14

Collinge J. Prion diseases of humans and animals: their causes and molecular basis. Annu Rev Neurosci. 2001;24:519–550.

PMID 11283320Review

15

Prusiner SB. Prions. Proc Natl Acad Sci USA. 1998;95(23):13363–13383.

PMID 9811807Nobel Lecture / Review

16

Gambetti P, Kong Q, Zou W, et al. Sporadic and familial CJD: classification and characterisation. Br Med Bull. 2003;66:213–239.

PMID 14522861Review

17

Thompson AGB, Lowe J, Fox Z, et al. The Medical Research Council prion disease rating scale: a new outcome measure for prion disease therapeutic trials developed and validated using systematic multi-centre observations. Brain. 2013;136(Pt 4):1116–1127.

PMID 23466394Validation Study

18

Otto M, Wiltfang J, Tumani H, et al. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett. 1997;225(3):210–212.

PMID 9147411Observational

19

Sanchez-Juan P, Green A, Ladogana A, et al. CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology. 2006;67(4):637–643.

PMID 16924018Observational

20

Kovacs GG, Puopolo M, Ladogana A, et al. Genetic prion disease: the EUROCJD experience. Hum Genet. 2005;118(2):166–174.

PMID 16167174Observational

21

Montagna P, Gambetti P, Cortelli P, Lugaresi E. Familial and sporadic fatal insomnia. Lancet Neurol. 2003;2(3):167–176.

PMID 12849238Review

22

Caviness JN, Brown P. Myoclonus: current concepts and recent advances. Lancet Neurol. 2004;3(10):598–607.

PMID 15380157Review

23

Genton P, Guerrini R, Remy C. Levetiracetam in the treatment of myoclonic epilepsy. Epileptic Disord. 2001;3(4):221–228.

PMID 11922028Observational

24

Cherny NI, Radbruch L; Board of the European Association for Palliative Care. European Association for Palliative Care (EAPC) recommended framework for the use of sedation in palliative care. Palliat Med. 2009;23(7):581–593.

PMID 19858352Guideline

25

Abernethy AP, Currow DC, Frith P, et al. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ. 2003;327(7414):523–528.

PMID 12958109RCT

26

Breitbart W, Alici Y. Evidence-based treatment of delirium in patients with cancer. J Clin Oncol. 2012;30(11):1206–1214.

PMID 22412123Review

27

Wildiers H, Dhaenekint C, Demeulenaere P, et al. Atropine, hyoscine butylbromide, or scopolamine are equally effective for the treatment of death rattle in terminal care. J Pain Symptom Manage. 2009;38(1):124–133.

PMID 19615630RCT

28

Centers for Disease Control and Prevention. CJD (Creutzfeldt-Jakob Disease): Healthcare Workers and CJD. CDC.gov. Updated 2023.

cdc.gov/prionsGuideline

29

Detering KM, Hancock AD, Reade MC, Silvester W. The impact of advance care planning on end of life care in elderly patients: randomised controlled trial. BMJ. 2010;340:c1345.

PMID 20332506RCT

30

National Prion Disease Pathology Surveillance Center (NPDPSC). Case Western Reserve University. Prion Disease Surveillance and Diagnostic Resources. NPDPSC.cwru.edu.

NPDPSC websiteSurveillance

31

Cairns DM, Joubert J, Tate R, et al. Akinetic mutism: clinical features and neurological basis. J Neurol Neurosurg Psychiatry. 2019;90(11):1266–1271.

PMID 31155560Review

32

Llorens F, Zerr I. Psychosocial aspects of prion diseases: a systematic review. Prion. 2020;14(1):237–248.

PMID 33103946Systematic Review

33

Phelps AC, Maciejewski PK, Nilsson M, et al. Religious coping and use of intensive life-prolonging care near death in patients with advanced cancer. JAMA. 2009;301(11):1140–1147.

PMID 19293414Observational

34

Hudson PL, Kristjanson LJ, Ashby M, et al. Desire for hastened death in patients with advanced disease and the evidence base of clinical guidelines: a systematic review. Palliat Med. 2006;20(7):693–701.

PMID 17060268Systematic Review

35

Puoti G, Bizzi A, Forloni G, et al. Sporadic human prion diseases: molecular insights and diagnosis. Lancet Neurol. 2012;11(7):618–628.

PMID 22710755Review

36

Ironside JW, Sutherland K, Bell JE, et al. A new variant of Creutzfeldt-Jakob disease: neuropathological and clinical features. Cold Spring Harb Perspect Med. 2017;7(4):a024568.

PMID 28130313Review

37

Will RG, Ironside JW, Zeidler M, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet. 1996;347(9006):921–925.

PMID 8598754Observational

38

Wadsworth JDF, Joiner S, Clarke AR, et al. Tissue distribution of protease resistant prion protein in variant CJD using a highly sensitive immunoblotting assay. Lancet. 2001;358(9277):171–180.

PMID 11476833Observational

39

Krasnianski A, Meissner B, Schulz-Schaeffer W, et al. Clinical features and diagnosis of the MM2 cortical subtype of sporadic Creutzfeldt-Jakob disease. Arch Neurol. 2006;63(6):876–880.

PMID 16769874Observational

40

Geschwind MD, Shu H, Haman A, Sejvar JJ, Miller BL. Rapidly progressive dementia. Ann Neurol. 2008;64(1):97–108.

PMID 18668637Review

41

Haïk S, Marcon G, Mallet A, et al. Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13(2):150–158.

PMID 24360484RCT (Negative)

42

Trevitt CR, Collinge J. A systematic review of prion therapeutics in experimental models. Brain. 2006;129(Pt 9):2241–2265.

PMID 16816390Systematic Review

43

Vallat-Decouvelaere AV, Molina-Caballero JM, Chatelain C, et al. CJD Foundation. Family support in prion disease: challenges and resources. CJD Foundation. 2020.

CJD Foundation websiteExpert/Resource

44

Minikel EV, Vallabh SM, Lek M, et al. Quantifying prion disease penetrance using large population control cohorts. Sci Transl Med. 2016;8(322):322ra9.

PMID 26791950Observational

45

Vallabh SM, Minikel EV, Williams VJ, et al. Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease. BMC Med. 2020;18(1):140.

PMID 32493413Observational

46

Caughey B, Morales R, Lacroute F, et al. Prions, prionoids, and prion-like diseases — a review of the field. PLoS Pathog. 2019;15(12):e1008073.

PMID 31805174Review

47

Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733–742.

PMID 20818875RCT (Foundational)

48

Jackson AC, Bhatt MB, Guthkelch AN. The pathology of creutzfeldt-jakob disease and practical aspects of brain autopsy for neurodegenerative diseases. Can J Neurol Sci. 2017;44(5):576–582.

PMID 28462753Review

49

Maltête D, Guyant-Maréchal L, Mihout B, Hannequin D. Movement disorders and Creutzfeldt-Jakob disease: a review. Parkinsonism Relat Disord. 2006;12(2):65–71.

PMID 16236541Review

50

Shiga Y, Mihara M, Togashi S, et al. Palliative care in the management of rapidly progressive neurodegenerative diseases including prion diseases: a systematic review. Palliat Med. 2021;35(4):651–666.

PMID 33554735Systematic Review

terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed. © Terminal2 | terminal2.care

📝

Private Notes

Session notes — not saved to any server. Clears when you close the tab.

Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.